Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole immediate release (IR) tablets

First Posted Date: 2014-10-10

Last Posted Date: 2014-10-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02261090

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Single rising doses of BI 1744 CL, solution for oral inhalation
Drug: Placebo
Drug: Tiotropium, fixed dose, solution for oral inhalation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02259959

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Persantin® commercial formulation
Drug: Persantin® new formulation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02259998

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Medium dose of BIBT 986 CL, per i.v. infusion
Drug: High dose of BIBT 986 CL, per i.v. infusion
Drug: Placebo
Drug: Low dose of BIBT 986 CL, per i.v. infusion
Drug: Lipopolysaccharide (LPS), single i.v. bolus

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02259881

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 113823 solution
Drug: BI 113823 tablet
Other: High fat, high calorie breakfast

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT02259972

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WAL 801 CL dry syrup new formulation
Drug: WAL 801 CL dry syrup conventional formulation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02260050

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Epinastine tablets
Drug: Epinastine syrup

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02260063

Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: KUC 7483 CL, immediate release tablet
Drug: KUC 7483 CL, particulate formulation
Drug: KUC 7483 CL, solution formulation
Device: Enterion™ capsule

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT02259920

Telmisartan in Mild to Moderate Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Low dose of telmisartan
Drug: High dose of telmisartan
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 134

Registration Number: NCT02260089

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIRT 2584 XX

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 55

Registration Number: NCT02259894

AI-Powered Research

Premium Access

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers

Telmisartan in Mild to Moderate Hypertensive Patients

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers